Literature DB >> 17445906

Anticholinergic use in hospitalised schizophrenic patients in Belgium.

Marc De Hert1, Martien Wampers, Ruud van Winkel, Jozef Peuskens.   

Abstract

This naturalistic study aims to evaluate the influence of antipsychotic treatment on the use of anticholinergics. The observed use of anticholinergics will give an indication of the occurrence of extrapyramidal side effects (EPS) in the different antipsychotic treatment conditions. The medication use of 1215 hospitalised patients with DSM-IV 295.xx diagnosis is recorded. Four antipsychotic treatment conditions are distinguished: 1) only first generation antipsychotics (FGA): patients receive one or a combination of first generation antipsychotics, 2) a combination of high potency FGA and second generation antipsychotics (SGA), 3) a combination of low potency FGA and SGA, and 4) only SGA: patients receive one or a combination of SGA. Antipsychotic treatment significantly influences the use of anticholinergics. Anticholinergic use is highest in patients treated with high potency FGA (whether or not in combination with SGA) as compared with patients only treated with SGA and patients combining SGA with low potency FGA. The two latter groups do not significantly differ. However, there were no significant differences in the prevalence of EPS with the exception of akathisia between FGA and SGA. Thus, through the use of anticholinergics, EPS induced by FGA can be effectively reduced.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17445906     DOI: 10.1016/j.psychres.2006.07.012

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  5 in total

1.  Safety and tolerability of antipsychotic polypharmacy.

Authors:  Juan A Gallego; Jimmi Nielsen; Marc De Hert; John M Kane; Christoph U Correll
Journal:  Expert Opin Drug Saf       Date:  2012-05-08       Impact factor: 4.250

2.  The use of antipsychotic and anticholinergic antiparkinson drugs in Norway after the withdrawal of orphenadrine.

Authors:  Pål Gjerden; Lars Slørdal; Jørgen G Bramness
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 3.  Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons.

Authors:  Christine Rummel-Kluge; Katja Komossa; Sandra Schwarz; Heike Hunger; Franziska Schmid; Werner Kissling; John M Davis; Stefan Leucht
Journal:  Schizophr Bull       Date:  2010-05-31       Impact factor: 9.306

4.  Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics.

Authors:  Hikaru Hori; Norio Yasui-Furukori; Naomi Hasegawa; Jun-Ichi Iga; Shinichiro Ochi; Kayo Ichihashi; Ryuji Furihata; Yoshitaka Kyo; Yoshikazu Takaesu; Takashi Tsuboi; Fumitoshi Kodaka; Toshiaki Onitsuka; Tsuyoshi Okada; Atsunobu Murata; Hiroko Kashiwagi; Hitoshi Iida; Naoki Hashimoto; Kazutaka Ohi; Hisashi Yamada; Kazuyoshi Ogasawara; Yuka Yasuda; Hiroyuki Muraoka; Masahide Usami; Shusuke Numata; Masahiro Takeshima; Hirotaka Yamagata; Tatsuya Nagasawa; Hiromi Tagata; Manabu Makinodan; Mikio Kido; Eiichi Katsumoto; Hiroshi Komatsu; Junya Matsumoto; Chika Kubota; Kenichiro Miura; Akitoyo Hishimoto; Koichiro Watanabe; Ken Inada; Hiroaki Kawasaki; Ryota Hashimoto
Journal:  Front Psychiatry       Date:  2022-05-17       Impact factor: 5.435

5.  In Vitro and In Vivo Characterization of the Alkaloid Nuciferine.

Authors:  Martilias S Farrell; John D McCorvy; Xi-Ping Huang; Daniel J Urban; Kate L White; Patrick M Giguere; Allison K Doak; Alison I Bernstein; Kristen A Stout; Su Mi Park; Ramona M Rodriguiz; Bradley W Gray; William S Hyatt; Andrew P Norwood; Kevin A Webster; Brenda M Gannon; Gary W Miller; Joseph H Porter; Brian K Shoichet; William E Fantegrossi; William C Wetsel; Bryan L Roth
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.